Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

RICHMOND, Va., March 10, 2011 /PRNewswire/ -- Insmed Inc. (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2010.

Key Recent Highlights:

  • Filed Investigational New Drug (IND) Application in February 2011 with the FDA to begin a phase 3 clinical trial for ARIKACE™ (liposomal amikacin for inhalation) in non-TB Mycobacteria (NTM) lung infections.
  • Successfully concluded 72 week phase 2b open-label study for ARIKACE for pseudomonas lung infections in cystic fibrosis (CF) patients.
  • Received positive opinion from European Medicines Agency (EMA) on Company's Pediatric Investigation Plan for ARIKACE in the CF indication.
  • Gained shareholder approval for conversion of preferred stock into common stock and 1:10 reverse stock split.

  • "Following the closure of our transformative business combination in December 2010, we have been aggressively moving forward with the development plan for ARIKACE, our phase 3 compound for pseudomonas lung infections for CF patients, and NTM lung infections," said Timothy Whitten, Insmed's President & CEO.  "We are well underway with the initial preparations and necessary work around these trials and continue to expect to begin accruing patients to the phase 3 trials in both indications in the second half of 2011, with results expected in the first half of 2013."

    Financial ResultsOn March 1, 2011, at a special meeting, our shareholders approved a one for 10 reverse stock split of our common stock, which became effective at 5:00 pm EST on March 2, 2011.  This reverse stock split is reflected in the shares outstanding and earnings per share calculations below.  

    Revenues for the fourth quarter ended December 31, 2010 were $1.3 million, as compared to $2.5 million for the corresponding period in 2009.  The $1.2 million decrease resulted from $0.6 million in lower cost r
    '/>"/>

    SOURCE Insmed Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Insmed to Host Second Quarter 2009 Conference Call
    2. Insmed Announces Addition to the Russell 3000(R) Index
    3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
    4. Insmed CEO Resigns Due to Health Concerns
    5. Insmed Announces First Quarter 2009 Financial Results
    6. Insmed Regains NASDAQ Compliance
    7. Insmed to Host First Quarter 2009 Conference Call
    8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
    9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
    10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
    11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/15/2014)... 2014 Omnia Education , the ... today announced the launch of a nationwide educational series ... Breast pain is the most common breast symptom for ... women report mild breast pain while evidence shows more ... lifespan. Along with breast pain and tenderness, FBC may ...
    (Date:11/15/2014)... , Nov. 14, 2014 Algenol Biofuels will present ... the Oceanographic Museum of Monaco . ... Monaco is an annual invitation-only event hosted by Innovator Capital, ... Other partners and sponsors include Prince Albert ... & Burling, Cranfield University, PR Newswire, the Monte-Carlo SBM, Oceanographic ...
    (Date:11/15/2014)... -- F. David Rollo , MD, Ph.D., FACC, FACNP ... Professional in the field of Medicine as a result ... Cell Point is a privately held biotechnology ... , Houston and ... ethylenedicysteine drug conjugate technology ("EC Technology"), In-Situ Hydrogel ("In ...
    (Date:11/12/2014)... SEATTLE , Nov. 12, 2014  ReachBio Research ... Seattle, WA ) announced today that it ... Tokyo, Japan ), giving Funakoshi non-exclusive distribution ... the life science research market within Japan ... promote ReachBio,s specialized contract research services to Japanese drug ...
    Breaking Biology Technology:Omnia Education Launches Nationwide Educational Series on Breast Pain and Fibrocystic Breast Changes Affecting Half of all Women 2Omnia Education Launches Nationwide Educational Series on Breast Pain and Fibrocystic Breast Changes Affecting Half of all Women 3Algenol Biofuels Selected to Present at CleanEquity Monaco 2015 2F. David Rollo, MD, Ph.D., FACC, FACNP is recognized by Continental Who's Who as a Pinnacle Professional 2Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 2Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 3
    ... Vasogen to also Raise $7.5 Million in Non-Dilutive ... MISSISSAUGA, ON, Aug. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... have entered into a definitive agreement, subject to shareholder and ... plan of arrangement and merger to continue as a publicly-traded ...
    ... , , SAN DIEGO, Aug. ... Chair Professor of the Department of Biochemistry and Director of ... and Technology (HKUST), has joined their scientific advisory board. ... recipient of China,s highest honor in the natural sciences, the ...
    ... , , ... Inc. (OTC Bulletin Board: BLFS), a leading manufacturer and marketer ... that it has entered into a non-exclusive distribution agreement with ... a member of the StemCell Group of companies, is a ...
    Cached Biology Technology:Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 3Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 4Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 5Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 6Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 7Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 8Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 9Professor Nancy Ip Joins aTyr Pharma's Scientific Advisory Board 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 3
    (Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
    (Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
    (Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
    Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2
    ... New Orleans, LA LSU Health Sciences Center New ... years by the National Center for Research Resources (NCRR), ... This Center of Biological Research Excellence (COBRE) grant funds ... enabling them to successfully compete nationally for research funding. ...
    ... more soot for the amount of fuel used than other ... as much soot as previously estimated, according to the first ... and the University of Colorado conducted the study and present ... Geophysical Research Letters . The primary sources ...
    ... in the current issue of the journal , Environmental ... in sea spray, attacks and damages DNA in the ... body,s way of ,disposing the toxin inadvertently converts it ... brevetoxins produced by the red tide ,organism, Karenia ...
    Cached Biology News:LSUHSC awarded $10M+ COBRE grant 2LSUHSC awarded $10M+ COBRE grant 3LSUHSC awarded $10M+ COBRE grant 4NOAA takes first broad look at soot from ships 2Aerosol toxins from red tides may cause long-term health threat 2
    Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
    ... Major Science Smart Minis 300V power ... with ever higher voltage, sufficient for SDS-PAGE, ... specifications ensure two pairs of terminator pairs ... Supply is designed for individuals to have ...
    ... is a premium quality recombinant form of ... is suitable for a wide range of ... and reproducible performance, each preparation is extensively ... assays. NovaTaq DNA Polymerase possesses an integral ...
    Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
    Biology Products: